바이오칩 시장 규모, 점유율, 동향 분석 보고서 : 유형별, 최종 용도별, 지역별, 부문별 예측(2025-2030년)

Biochip Market Growth & Trends:

The global biochip market size is estimated to reach USD 26.30 billion by 2030, expanding at a CAGR of 11.41% from 2025 to 2030, according to a new report by Grand View Research, Inc. The rising requirement for drug discovery and development coupled with the adoption of personalized medicine is likely to favor the industry's growth. Furthermore, the rise in the implementation of next-generation sequencing by biotechnology companies around the globe is pushing product demand. For instance, in December 2021, Abbott received CE Mark for the i-STAT TBI Plasma test, a portable analyzer for Traumatic Brain Injury (TBI) blood. Hence, the company is permitted to expand its footprint in the European Union. The innovation in sequencing techniques has allowed researchers to decode DNA molecules up to the level of the complete human genome.

Ion Torrent chip by Thermo Fisher Scientific is one of the technologies based on sequencing by the technique of synthesis. The chip is an advancement in the Next-Generation Sequencing (NGS) technology that makes massively parallel sequencing cost-effective for every lab. Hence, the development of biochips to enhance the NGS application is anticipated to support the growth of the industry. Similarly, increasing government-based initiatives to promote the domestic production of biochips is likely to support the growth in the coming years. This strategic initiative is to match the local demand for the product with the supply. For instance, in July 2022, SiPhox, Inc. received a grant worth USD 681,631 from the Baker-Polito Administration.

The financial support is to accelerate the development of a manufacturing facility for the mass production of pluggable photonic biochips. It is estimated to accelerate the output to around 5,000 biochips per month from around 100 per month to match the rising demand from biotech segments including drug discovery, vaccine development, and distributed diagnostics. Such investments are likely to supplement the industry growth in the coming years. The COVID-19 pandemic is estimated to have a positive impact on industry growth during the forecasted period. Various companies collaborated to develop innovative solutions to deal with the pandemic. For instance, in March 2020, SkyWater Technology announced the collaboration with MGI, to supply essential components for COVID-19 sequencing, including microfluidic MEMS devices.

The growing requirement for personalized medicine is likely to become a key application area for the industry in the coming years. Since biochip is emerging as an important component in molecular diagnostics, their use in point-of-care diagnostics is anticipated to smooth the development of personalized medicines. In addition, gene expression profiling through microarrays is expected to enhance the progress of personalized treatment for cancer based on molecular classification. However, the cost involved in the manufacturing of biochips is considerably high, resulting in high pricing for end-users. For instance, Josep Carreras Leukaemia Research Institute (IJC) provides microarray to researchers. The cost of GeneChip Human Gene 2.0 ST for whole-transcript expression analysis & profiling ranges from USD 456 to 593 for fresh samples.

Biochip Market Report Highlights:

• The DNA chips type segment accounted for the largest revenue share in 2024 due to the high demand for rapid and accurate detection of cancer
• The drug discovery application segment for lab-on-chip is anticipated to grow at a faster rate during the forecast period as the biochip helps lower the overall cost of drug discovery & development
• The biotechnology and pharmaceutical companies end-user segment captured a significant revenue share in 2024 due to the need for personalized medicines along with the increasing drug discovery & development
• North America held the largest revenue share in 2024 owing to high R&D investment coupled with the accessibility of capital through venture capitalists for startups and the application development of biochips in the region
• Asia Pacific is projected to register the fastest CAGR from 2025 to 2030 owing to various initiatives by local governments to promote domestic product manufacturing

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
  • 1.1.1. Type Segment
  • 1.1.2. End Use Segment
• 1.2. Regional Scope
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Primary Research
• 1.6. Information or Data Analysis:
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Validation
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. List of Abbreviations
• 1.11. Objective

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Increase in adoption of next-generation sequencing
    • 3.2.1.2. Growing R&D in proteomics and genomics
    • 3.2.1.3. Presence of an extensive drug-development pipeline
    • 3.2.1.4. Increasing adoption of personalized medicine
    • 3.2.1.5. Rapid technological advances in biochip technology
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. High cost of manufacturing
• 3.3. Industry Analysis Tools
  • 3.3.1. Porter's Five Forces Analysis
  • 3.3.2. PESTEL Analysis
  • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Type Group Business Analysis

• 4.1. Type Segment Dashboard
• 4.2. Biochip Market Type Movement Analysis
• 4.3. Biochip Market Size & Trend Analysis, by Type, 2018 to 2030 (USD Million)
• 4.4. DNA Chips
  • 4.4.1. DNA chips market estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.4.2. Cancer Diagnosis and Treatment
    • 4.4.2.1. Cancer diagnosis and treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.4.3. Gene Expression
    • 4.4.3.1. Gene expression market estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.4.4. SNP Genotyping
    • 4.4.4.1. SNP genotyping market estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.4.5. Genomics
    • 4.4.5.1. Genomics market estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.4.6. Drug Discovery
    • 4.4.6.1. Drug discovery market estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.4.7. Agricultural Biotechnology
    • 4.4.7.1. Agricultural biotechnology market estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.4.8. Others
    • 4.4.8.1. Others market estimates and forecasts, 2018 - 2030 (USD Million)
• 4.5. Protein Chips
  • 4.5.1. Protein chips market estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.5.2. Proteomics
    • 4.5.2.1. Proteomics market estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.5.3. Expression Profiling
    • 4.5.3.1. Expression profiling market estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.5.4. Diagnostics
    • 4.5.4.1. Diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.5.5. HTS
    • 4.5.5.1. HTS market estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.5.6. Drug Discovery
    • 4.5.6.1. Drug discovery market estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.5.7. Others
    • 4.5.7.1. Others market estimates and forecasts, 2018 - 2030 (USD Million)
• 4.6. Lab-on-chip
  • 4.6.1. Lab-on-chip market estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.6.2. Genomics
    • 4.6.2.1. Genomics market estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.6.3. IVD & POC
    • 4.6.3.1. IVD & POC market estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.6.4. Proteomics
    • 4.6.4.1. Proteomics market estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.6.5. Drug Discovery
    • 4.6.5.1. Drug discovery market estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.6.6. Others
    • 4.6.6.1. Others market estimates and forecasts, 2018 - 2030 (USD Million)
• 4.7. Tissue Arrays
  • 4.7.1. Tissue arrays market estimates and forecasts, 2018 - 2030 (USD Million)
• 4.8. Cell Arrays
  • 4.8.1. Cell arrays market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 5. End Use Business Analysis

• 5.1. End Use Segment Dashboard
• 5.2. Biochip Market End Use Movement Analysis
• 5.3. Biochip Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
• 5.4. Biotechnology & Pharmaceutical Companies
  • 5.4.1. Biotechnology & pharmaceutical companies market estimates and forecasts, 2018 - 2030 (USD Million)
• 5.5. Hospitals & Diagnostic Centers
  • 5.5.1. Hospitals & diagnostic centers market estimates and forecasts, 2018 - 2030 (USD Million)
• 5.6. Academic & Research Institute
  • 5.6.1. Academic & research institute market estimates and forecasts, 2018 - 2030 (USD Million)
• 5.7. Others
  • 5.7.1. Others market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 6. Regional Business Analysis by Type, End Use

• 6.1. Regional Dashboard
• 6.2. Market Size & Forecast and Trend Analysis, 2024 & 2030
• 6.3. North America
  • 6.3.1. North America Biochip Market, 2018 - 2030 (USD Million)
  • 6.3.2. U.S.
    • 6.3.2.1. Key Country Dynamics
    • 6.3.2.2. Competitive Scenario
    • 6.3.2.3. Target Disease Prevalence
    • 6.3.2.4. U.S. Biochip Market, 2018 - 2030 (USD Million)
  • 6.3.3. Canada
    • 6.3.3.1. Key Country Dynamics
    • 6.3.3.2. Competitive Scenario
    • 6.3.3.3. Target Disease Prevalence
    • 6.3.3.4. Canada Biochip Market, 2018 - 2030 (USD Million)
  • 6.3.4. Mexico
    • 6.3.4.1. Key Country Dynamics
    • 6.3.4.2. Competitive Scenario
    • 6.3.4.3. Target Disease Prevalence
    • 6.3.4.4. Mexico Biochip Market, 2018 - 2030 (USD Million)
• 6.4. Europe
  • 6.4.1. Europe Biochip Market, 2018 - 2030 (USD Million)
  • 6.4.2. UK
    • 6.4.2.1. Key Country Dynamics
    • 6.4.2.2. Competitive Scenario
    • 6.4.2.3. Target Disease Prevalence
    • 6.4.2.4. UK Biochip Market, 2018 - 2030 (USD Million)
  • 6.4.3. Germany
    • 6.4.3.1. Key Country Dynamics
    • 6.4.3.2. Competitive Scenario
    • 6.4.3.3. Target Disease Prevalence
    • 6.4.3.4. Germany Biochip Market, 2018 - 2030 (USD Million)
  • 6.4.4. France
    • 6.4.4.1. Key Country Dynamics
    • 6.4.4.2. Competitive Scenario
    • 6.4.4.3. Target Disease Prevalence
    • 6.4.4.4. France Biochip Market, 2018 - 2030 (USD Million)
  • 6.4.5. Italy
    • 6.4.5.1. Key Country Dynamics
    • 6.4.5.2. Competitive Scenario
    • 6.4.5.3. Target Disease Prevalence
    • 6.4.5.4. Italy Biochip Market, 2018 - 2030 (USD Million)
  • 6.4.6. Spain
    • 6.4.6.1. Key Country Dynamics
    • 6.4.6.2. Competitive Scenario
    • 6.4.6.3. Target Disease Prevalence
    • 6.4.6.4. Spain Biochip Market, 2018 - 2030 (USD Million)
  • 6.4.7. Denmark
    • 6.4.7.1. Key Country Dynamics
    • 6.4.7.2. Competitive Scenario
    • 6.4.7.3. Denmark Biochip Market, 2018 - 2030 (USD Million)
  • 6.4.8. Sweden
    • 6.4.8.1. Key Country Dynamics
    • 6.4.8.2. Competitive Scenario
    • 6.4.8.3. Target Disease Prevalence
    • 6.4.8.4. Sweden Biochip Market, 2018 - 2030 (USD Million)
  • 6.4.9. Norway
    • 6.4.9.1. Key Country Dynamics
    • 6.4.9.2. Competitive Scenario
    • 6.4.9.3. Target Disease Prevalence
    • 6.4.9.4. Norway Biochip Market, 2018 - 2030 (USD Million)
• 6.5. Asia Pacific
  • 6.5.1. Asia Pacific Biochip Market, 2018 - 2030 (USD Million)
  • 6.5.2. Japan
    • 6.5.2.1. Key Country Dynamics
    • 6.5.2.2. Competitive Scenario
    • 6.5.2.3. Japan Biochip Market, 2018 - 2030 (USD Million)
  • 6.5.3. China
    • 6.5.3.1. Key Country Dynamics
    • 6.5.3.2. Competitive Scenario
    • 6.5.3.3. China Biochip Market, 2018 - 2030 (USD Million)
  • 6.5.4. India
    • 6.5.4.1. Key Country Dynamics
    • 6.5.4.2. Competitive Scenario
    • 6.5.4.3. Target Disease Prevalence
    • 6.5.4.4. India Biochip Market, 2018 - 2030 (USD Million)
  • 6.5.5. Australia
    • 6.5.5.1. Key Country Dynamics
    • 6.5.5.2. Competitive Scenario
    • 6.5.5.3. Target Disease Prevalence
    • 6.5.5.4. Australia Biochip Market, 2018 - 2030 (USD Million)
  • 6.5.6. Thailand
    • 6.5.6.1. Key Country Dynamics
    • 6.5.6.2. Competitive Scenario
    • 6.5.6.3. Target Disease Prevalence
    • 6.5.6.4. Thailand Biochip Market, 2018 - 2030 (USD Million)
  • 6.5.7. South Korea
    • 6.5.7.1. Key Country Dynamics
    • 6.5.7.2. Competitive Scenario
    • 6.5.7.3. Target Disease Prevalence
    • 6.5.7.4. South Korea Biochip Market, 2018 - 2030 (USD Million)
• 6.6. Latin America
  • 6.6.1. Latin America Biochip Market, 2018 - 2030 (USD Million)
  • 6.6.2. Brazil
    • 6.6.2.1. Key Country Dynamics
    • 6.6.2.2. Competitive Scenario
    • 6.6.2.3. Target Disease Prevalence
    • 6.6.2.4. Brazil Biochip Market, 2018 - 2030 (USD Million)
  • 6.6.3. Argentina
    • 6.6.3.1. Key Country Dynamics
    • 6.6.3.2. Competitive Scenario
    • 6.6.3.3. Target Disease Prevalence
    • 6.6.3.4. Argentina Biochip Market, 2018 - 2030 (USD Million)
• 6.7. MEA
  • 6.7.1. MEA Biochip Market, 2018 - 2030 (USD Million)
  • 6.7.2. South Africa
    • 6.7.2.1. Key Country Dynamics
    • 6.7.2.2. Competitive Scenario
    • 6.7.2.3. Target Disease Prevalence
    • 6.7.2.4. South Africa Biochip Market, 2018 - 2030 (USD Million)
  • 6.7.3. Saudi Arabia
    • 6.7.3.1. Key Country Dynamics
    • 6.7.3.2. Competitive Scenario
    • 6.7.3.3. Target Disease Prevalence
    • 6.7.3.4. Saudi Arabia Biochip Market, 2018 - 2030 (USD Million)
  • 6.7.4. UAE
    • 6.7.4.1. Key Country Dynamics
    • 6.7.4.2. Competitive Scenario
    • 6.7.4.3. Target Disease Prevalence
    • 6.7.4.4. UAE Biochip Market, 2018 - 2030 (USD Million)
  • 6.7.5. Kuwait
    • 6.7.5.1. Key Country Dynamics
    • 6.7.5.2. Competitive Scenario
    • 6.7.5.3. Target Disease Prevalence
    • 6.7.5.4. Kuwait Biochip Market, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Company Categorization
• 7.2. Strategy Mapping
• 7.3. Company Market Position Analysis, 2024
• 7.4. Company Profiles/Listing
  • 7.4.1. Agilent Technologies
    • 7.4.1.1. Overview
    • 7.4.1.2. Financial Performance
    • 7.4.1.3. Product Benchmarking
    • 7.4.1.4. Strategic Initiatives
  • 7.4.2. PerkinElmer, Inc.
    • 7.4.2.1. Overview
    • 7.4.2.2. Financial Performance
    • 7.4.2.3. Product Benchmarking
    • 7.4.2.4. Strategic Initiatives
  • 7.4.3. Illumina, Inc.
    • 7.4.3.1. Overview
    • 7.4.3.2. Financial Performance
    • 7.4.3.3. Product Benchmarking
    • 7.4.3.4. Strategic Initiatives
  • 7.4.4. Bio-Rad Laboratories, Inc.
    • 7.4.4.1. Overview
    • 7.4.4.2. Financial Performance
    • 7.4.4.3. Product Benchmarking
    • 7.4.4.4. Strategic Initiatives
  • 7.4.5. Standard BioTools Inc.
    • 7.4.5.1. Overview
    • 7.4.5.2. Financial Performance
    • 7.4.5.3. Product Benchmarking
    • 7.4.5.4. Strategic Initiatives
  • 7.4.6. GE HealthCare
    • 7.4.6.1. Overview
    • 7.4.6.2. Financial Performance
    • 7.4.6.3. Product Benchmarking
    • 7.4.6.4. Strategic Initiatives
  • 7.4.7. IBIOCHIPS
    • 7.4.7.1. Overview
    • 7.4.7.2. Financial Performance
    • 7.4.7.3. Product Benchmarking
    • 7.4.7.4. Strategic Initiatives
  • 7.4.8. LI-COR, Inc.
    • 7.4.8.1. Overview
    • 7.4.8.2. Financial Performance
    • 7.4.8.3. Product Benchmarking
    • 7.4.8.4. Strategic Initiatives
  • 7.4.9. Cellix Ltd
    • 7.4.9.1. Overview
    • 7.4.9.2. Financial Performance
    • 7.4.9.3. Product Benchmarking
    • 7.4.9.4. Strategic Initiatives
  • 7.4.10. Randox Laboratories Ltd.
    • 7.4.10.1. Overview
    • 7.4.10.2. Financial Performance
    • 7.4.10.3. Product Benchmarking
    • 7.4.10.4. Strategic Initiatives